Jared Marquardt, MD
Emergency Medicine · Bismarck, NDNPI 1235541756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $816 and has fallen 74.7% since, to $206 in 2025. Among emergency medicine clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$469
- Amgen$360
- Pfizer$259
- AbbVie$256
- Merck$201
- Johnson & Johnson$185
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,02598%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $469 |
| Amgen | 15 | $360 |
| Pfizer | 17 | $259 |
| AbbVie(2 entities) | 15 | $256 |
| Merck | 12 | $201 |
| Johnson & Johnson | 18 | $185 |
| Astellas Pharma US Inc | 8 | $169 |
| Sanofi-aventis U.S. LLC | 11 | $161 |
| Lilly USA, LLC | 11 | $154 |
| Boehringer Ingelheim | 7 | $126 |
| Novartis | 6 | $84 |
| Phathom Pharmaceuticals, Inc. | 6 | $80 |
| Lundbeck LLC | 4 | $73 |
| Mylan Specialty L.p. | 4 | $58 |
| Organogenesis Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Sanofi Pasteur Inc. | 2 | $40 |
| Incyte Corporation | 2 | $32 |
| Myriad Women's Health, Inc. | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Bayer | 2 | $28 |
| Philips North America LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Cepheid | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| GSK | 1 | $14 |
| Medtronic | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
| Boston Scientific | 1 | $12 |
How this compares
$3,100 in reported general payments places this provider in the 95th percentile of 104 emergency medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $129,731 |
| OzempicSemaglutide | 56 | $50,654 |
| TrulicityDulaglutide | 30 | $34,831 |
| JardianceEmpagliflozin | 36 | $30,912 |
| MyrbetriqMirabegron | 60 | $29,167 |
| XareltoRivaroxaban | 31 | $24,733 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $22,286 |
| MounjaroTirzepatide | 19 | $21,598 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $18,326 |
| VraylarCariprazine Hcl | 13 | $16,273 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 51 | $16,260 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $13,517 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $11,566 |
| FarxigaDapagliflozin Propanediol | 17 | $10,648 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 47 | $10,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $259 | $145,991222 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $154 | $56,42949 claims |
| Novo NordiskOzempic | $469 | $50,65456 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $126 | $38,27752 claims |
| GSKAnoro Ellipta, Shingrix, Trelegy Ellipta, Breo Ellipta | $14 | $36,05696 claims |
| Astellas Pharma US IncMyrbetriq | $169 | $29,16760 claims |
| MerckJanumet, Januvia | $201 | $24,73827 claims |
| Johnson & JohnsonXarelto | $185 | $24,73331 claims |
| AbbVieVraylar | $256 | $16,27313 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $161 | $13,51715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 emergency medicine providers in North Dakota.
Other emergency medicine in Bismarck
- Jeffrey RundioBismarck$166
- Nigeria StahlBismarck$137
- Kadon HintzBismarck$127
- Mark DetwillerBismarck$82
- Andrew SwensonBismarck$72
- Matthew ZimnyBismarck$59
- Guy ConnellBismarck$55
- Davin HatlestadBismarck$51
- Jordan DeraneyBismarck$47
- Justin ReisenauerBismarck$41
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.